Equities research analysts forecast that PRA Health Sciences, Inc. (NASDAQ:PRAH) will post $447.88 million in sales for the current fiscal quarter, Zacks reports. Six analysts have issued estimates for PRA Health Sciences’ earnings, with estimates ranging from $445.00 million to $455.90 million. PRA Health Sciences reported sales of $455.85 million during the same quarter last year, which indicates a negative year-over-year growth rate of 1.7%. The firm is expected to report its next quarterly earnings report on Monday, August 7th.

According to Zacks, analysts expect that PRA Health Sciences will report full-year sales of $447.88 million for the current financial year, with estimates ranging from $1.82 billion to $1.84 billion. For the next financial year, analysts expect that the company will report sales of $2.07 billion per share, with estimates ranging from $2.04 billion to $2.10 billion. Zacks’ sales calculations are a mean average based on a survey of research firms that follow PRA Health Sciences.

PRA Health Sciences (NASDAQ:PRAH) last posted its earnings results on Monday, August 7th. The medical research company reported $0.79 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.05. PRA Health Sciences had a return on equity of 21.87% and a net margin of 5.85%. The company had revenue of $457.90 million for the quarter, compared to analyst estimates of $447.79 million. During the same period last year, the company earned $0.63 earnings per share. The business’s revenue was up .5% compared to the same quarter last year.

A number of research firms have recently commented on PRAH. BidaskClub downgraded shares of PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Bank of America Corporation began coverage on shares of PRA Health Sciences in a research note on Monday, June 26th. They set a “buy” rating and a $89.00 price objective for the company. Credit Suisse Group restated an “outperform” rating and set a $76.00 price objective (up from $69.00) on shares of PRA Health Sciences in a research note on Tuesday, June 6th. Jefferies Group LLC set a $73.00 price objective on shares of PRA Health Sciences and gave the stock a “buy” rating in a research note on Thursday, June 1st. Finally, Citigroup Inc. restated a “buy” rating and set a $90.00 price objective (up from $73.00) on shares of PRA Health Sciences in a research note on Wednesday, June 28th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $73.00.

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in shares of PRA Health Sciences by 3.8% in the first quarter. Vanguard Group Inc. now owns 4,659,592 shares of the medical research company’s stock worth $303,946,000 after buying an additional 170,812 shares during the last quarter. BlackRock Inc. boosted its stake in shares of PRA Health Sciences by 43,947.8% in the first quarter. BlackRock Inc. now owns 2,857,381 shares of the medical research company’s stock worth $186,387,000 after buying an additional 2,850,894 shares during the last quarter. Acadian Asset Management LLC boosted its stake in shares of PRA Health Sciences by 0.4% in the first quarter. Acadian Asset Management LLC now owns 2,153,016 shares of the medical research company’s stock worth $140,441,000 after buying an additional 7,769 shares during the last quarter. MARSHALL WACE ASIA Ltd purchased a new stake in shares of PRA Health Sciences during the first quarter worth about $82,935,000. Finally, Marshall Wace North America L.P. purchased a new stake in shares of PRA Health Sciences during the first quarter worth about $82,935,000.

ILLEGAL ACTIVITY WARNING: “PRA Health Sciences, Inc. (PRAH) Expected to Announce Quarterly Sales of $447.88 Million” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/08/pra-health-sciences-inc-prah-expected-to-announce-quarterly-sales-of-447-88-million.html.

PRA Health Sciences (PRAH) opened at 74.23 on Tuesday. The firm’s 50-day moving average price is $75.01 and its 200 day moving average price is $66.37. The company has a market capitalization of $4.64 billion, a price-to-earnings ratio of 44.34 and a beta of 0.45. PRA Health Sciences has a 12-month low of $46.52 and a 12-month high of $79.98.

About PRA Health Sciences

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Get a free copy of the Zacks research report on PRA Health Sciences (PRAH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.